1. Are we victims of our own success in cardiovascular therapeutics?

   • Afshin Farzaneh-Far
   • Peter Libby

   Invited Commentary Pages: 1 - 2

2. Clinical trials report

   • Michael Clearfield

   OriginalPaper Pages: 5 - 9

3. Statin therapy: Is the percent reduction or the attained low-density lipoprotein cholesterol level more important?

   • Tracie C. Collins
   • Peter H. Jones

   OriginalPaper Pages: 10 - 17

4. Statin therapy in renal disease: Harmful or protective?

   • Peter A. McCullough
   • Leslie R. Rocher

   OriginalPaper Pages: 18 - 24

5. Statin therapy in cardiovascular diseases other than atherosclerosis

   • Dominique Beaudry
   • Kenneth E. Stone
   • Robert Chilton

   OriginalPaper Pages: 25 - 32

6. Statins and biomarkers of inflammation

   • Sridevi Devaraj
   • Jason Rogers
   • Ishwarlal Jialal

   OriginalPaper Pages: 33 - 41

7. Clinical trials report

   • Michael H. Davidson

   OriginalPaper Pages: 45 - 47

8. Will torcetrapib be the next big thing in coronary heart disease risk reduction?

   • James M. McKenney
   • John A. Hoekstra

   OriginalPaper Pages: 48 - 56

9. Modifying the anti-inflammatory effects of high-density lipoprotein

   • Benjamin J. Ansell
   • Gregg C. Fonarow
   • Alan M. Fogelman

   OriginalPaper Pages: 57 - 63

10. Update on PPAR agonists: The clinical significance of FIELD and PROACTIVE

    • Jennifer G. Robinson

    OriginalPaper Pages: 64 - 71

11. PPARδ agonists and metabolic diseases

    • Kihwa Kang
    • Ben Hatano
    • Chih-Hao Lee

    OriginalPaper Pages: 72 - 77

12. Squalene synthase inhibition: A novel target for the management of dyslipidemia

    • Michael H. Davidson

    OriginalPaper Pages: 78 - 80

13. Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol

    • Peter P. Toth

    OriginalPaper Pages: 81 - 88